Founded Year

2015

Stage

Series B | Alive

Total Raised

$169.72M

Last Raised

$80M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+27 points in the past 30 days

About NMD Pharma

NMD Pharma is a biotechnology company involved in developing therapeutics for neuromuscular diseases. The company works on small molecule inhibitors targeting skeletal muscle-specific ClC-1 ion channels, which are related to muscle activation failures causing weakness and fatigue. NMD Pharma sells to the healthcare sector and addresses conditions such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth's disease, and sarcopenia. It was founded in 2015 and is based in Aarhus Nord, Denmark.

Headquarters Location

Palle Juul-Jensens Blvd. 82

Aarhus Nord, 8200,

Denmark

+45 52 66 57 00

Loading...

Loading...

Research containing NMD Pharma

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned NMD Pharma in 2 CB Insights research briefs, most recently on Jun 13, 2025.

NMD Pharma Patents

NMD Pharma has filed 11 patents.

The 3 most popular patent topics include:

  • electrophysiology
  • ion channels
  • ion channel toxins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/19/2020

2/11/2025

Alkynes, Cyclopentanes, Cyclopropanes, Estranes, Ketones

Grant

Application Date

6/19/2020

Grant Date

2/11/2025

Title

Related Topics

Alkynes, Cyclopentanes, Cyclopropanes, Estranes, Ketones

Status

Grant

Latest NMD Pharma News

Global Charcot-Marie-Tooth Disease Market Set For 20.6% Growth, Reaching 2.8 Billion By 2029

Jul 5, 2025

Save 30% on all global market reports with code ONLINE30 – stay informed on tariff changes, macroeconomic trends, and more.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 / EINPresswire.com / -- Save 30% on all global market reports with code ONLINE30 – stay informed on tariff changes, macroeconomic trends, and more. The charcot-marie-tooth disease market size has grown exponentially in recent years. It will grow from $1.09 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate CAGR of 20.9%. The growth in the historic period can be attributed to increasing public awareness of genetic neuropathie, growing use of genetic counseling services, increased physician education on rare diseases, enhanced patient advocacy campaigns, and wider availability of neurophysiological testing. What Is The Projected Market Size And Growth Rate For The Charcot-Marie-Tooth Disease Market? It is expected to see exponential growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate CAGR of 20.6%. The growth in the forecast period can be attributed to early screening programs for inherited disorders, growth in neurology and neuromuscular specialty clinics, enhanced reimbursement for rare disease treatments, expansion of insurance coverage for genetic testing, and rise in healthcare spending. Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample_request?id=24501&type=smp How Does The Surge In Healthcare Expenditure Impact The Growth Of The Charcot-Marie-Tooth Disease Market? The surge in healthcare expenditure is anticipated to fuel the growth of the charcot-marie-tooth disease market going forward. Healthcare expenditure is the overall spending on medical services, supplies, and activities aimed at maintaining or improving health. Healthcare expenditure is rising due to the development and adoption of advanced medical technologies, which involve high costs for research, equipment, and specialized training, thereby increasing the overall spending on healthcare services. The rise in healthcare expenditure supports the demand for charcot-marie-tooth disease treatment by enabling greater investment in specialized therapies, diagnostic tools, and supportive care services, thereby improving access to comprehensive disease management. Who Are The Key Players And Innovators In The Charcot-Marie-Tooth Disease Market Major companies operating in the charcot-marie-tooth disease market are F-Hoffmann-La-Roche-Ltd, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., Chong Kun Dang Pharmaceutical Corp., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Acceleron Pharma, Affectis Pharmaceuticals AG, NMD Pharma, Pharnext SA, MedDay Pharmaceuticals, Inflectis BioScience, Helixmith Co. Ltd., Addex Therapeutics, Augustine Therapeutics, DTx Pharma Inc., ENCell Co Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/charcot-marie-tooth-disease-global-market-report What Are The Emerging Trends In The Charcot-Marie-Tooth Disease Market Major companies operating in the charcot-marie-tooth disease market are focusing on developing advanced solutions, such as mesenchymal stem cell therapies, to offer ease of isolation and expansion from various tissue sources. Mesenchymal stem cell therapies use versatile cells capable of developing into different tissue types to aid in healing and reducing inflammation in various health conditions. How Is The Charcot-Marie-Tooth Disease Market Categorized? The charcot-marie-tooth disease market covered in this report is segmented – 1 By Disease Type: CMT 1, CMT 2, CMT 3, Other Disease Types 2 By Drug Type: Nonsteroidal Anti-Inflammatory Drugs, Cyclooxygenase-2 Inhibitors, Tricyclic Antidepressants, Anticonvulsants, Analgesics, Pipeline Drug 3 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies In Which Regions Can Market Growth Be Identified? North America was the largest region in the charcot-marie-tooth disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the charcot-marie-tooth disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. Browse Through More Similar Reports By The Business Research Company: Pet Dental Health Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/pet-dental-health-global-market-report Dental Insurance Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/dental-insurance-global-market-report Rare Diseases Treatment Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report About The Business Research Company With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 310-496-7795 Asia +44 2071930708 Europe +44 7882 955267 Email us at info@tbrc.info Follow us on: LinkedIn: https://in.linkedin.com/company/the-business-research-company YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

NMD Pharma Frequently Asked Questions (FAQ)

  • When was NMD Pharma founded?

    NMD Pharma was founded in 2015.

  • Where is NMD Pharma's headquarters?

    NMD Pharma's headquarters is located at Palle Juul-Jensens Blvd. 82, Aarhus Nord.

  • What is NMD Pharma's latest funding round?

    NMD Pharma's latest funding round is Series B.

  • How much did NMD Pharma raise?

    NMD Pharma raised a total of $169.72M.

  • Who are the investors of NMD Pharma?

    Investors of NMD Pharma include Roche Venture Fund, INKEF Capital, Novo Holdings, Jeito Capital, Lundbeckfond Ventures and 7 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.